Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news
Many Non-Hodgkin's Lymphoma patients can skip radiation, collaborative study finds
(University of Arizona Health Sciences) Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 6, 2020 Category: Cancer & Oncology Source Type: news
FDA grants Fast Track designation to Calibr's 'switchable' CAR-T cell cancer therapy
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news
Non-Hodgkin's Lymphoma
Title: Non-Hodgkin ' s LymphomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/31/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 31, 2020 Category: Cancer & Oncology Source Type: news
Mayo Clinic Q and A: New blood cancer treatment options with chimeric antigen receptor-T cell therapy
Dear Mayo Clinic: My brother was diagnosed with non-Hodgkin lymphoma a few years ago and has had several recurrences. I was reading about something called chimeric antigen receptor-T cell therapy (CAR-T cell therapy) and was wondering how it works and if he might be a candidate for it? Answer: CAR-T cell therapy is a relatively new treatment that [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 29, 2020 Category: Databases & Libraries Source Type: news
FDA grants Breakthrough Therapy Designation for Roche ’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Garraway, M...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news
Judge Puts Cloud Over Settlement of Roundup Cancer Claims
An agreement for the weedkiller ’s maker to pay more than $10 billion to end litigation may not get court approval. (Source: NYT Health)
Source: NYT Health - July 7, 2020 Category: Consumer Health News Authors: Patricia Cohen Tags: Hazardous and Toxic Substances Suits and Litigation (Civil) Defoliants and Herbicides Non-Hodgkin ' s Lymphoma Bayer AG Monsanto Company Chhabria, Vince Girdhari Feinberg, Kenneth R Roundup Source Type: news
Highlights in Non-Hodgkin Lymphoma From ASCO 2020 Highlights in Non-Hodgkin Lymphoma From ASCO 2020
Highlights in non-Hodgkin lymphoma from the ASCO 2020 virtual annual meeting include new data on CAR T cells in relapsed/refractory NHL, and Bcl-2 inhibition and chemoimmunotherapy in Richter syndrome.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news
Blood cancer symptoms: Swelling in this part of the body could be a warning sign
BLOOD CANCER - there are three main types: leukaemia, lymphoma and myeloma. Those with non-Hodgkin lymphoma may experience swelling, but where in the body? (Source: Daily Express - Health)
Source: Daily Express - Health - June 18, 2020 Category: Consumer Health News Source Type: news
Roche presents updated data on novel CD20xCD3 bispecific cancer immunotherapy glofitamab in people with heavily pre-treated non-Hodgkin lymphomas
Basel, 12 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data on one of its investigational CD20xCD3 T-cell engaging bispecific antibodies, glofitamab (formerly known as CD20-TCB), in people with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). Updated results from the phase I dose-escalation NP30179 study [NCT03075696] of glofitamab, administered via intravenous infusion for a fixed-duration of up to 12 21-day cycles, showed durable complete responses (CRs) in heavily pre-treated patients who had received a median of three prior lines of therapy. These data feature in an oral presentation (...
Source: Roche Investor Update - June 12, 2020 Category: Pharmaceuticals Source Type: news
Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings
The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Caron A. Jacobson, MD Source Type: news
Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2020 Category: Pharmaceuticals Source Type: news
Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news
A new immunotherapeutic agent for children and adolescents with advanced lymphoma
(Comprehensive Cancer Centre Gustave Roussy) The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine. It establishes a new standard treatment with an improved cure rate for children with advanced non-Hodgkin lymphoma, mainly Burkitt lymphoma. It supports the value of an immunotherapeutic agent, which was authorised in March 2020 by the European Commission for the treatment of a rare childhood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2020 Category: Cancer & Oncology Source Type: news
Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL
Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
